In the similar context, treatment with Z-Phe-Ala-diazomethylketone (PADK; also known as ZFAD), a CTSB activator, reduced Aβ deposition and improved synaptic and cognitive dysfunctions in an APP/presenilin-1 (PS1) and mild cognitive impairment (MCI) mouse model [112]. Here, PSEN1 is linked to Cognitive impairment.